Company: APM
Filing Date: 2025-10-06
Form Type: S-4
Source: 0001213900-25-096656
Chunk: 485

Company: Aptorum Group Ltd
Filing Date: 2025-10-06
Form: S-4
Chunk 485
---
orum Group Limited(1) |     |              |            |   |     |              |            |   |     |              |            |   |
| – Basic(1)                                                  |     | $            |      (0.78 | ) |     | $            |      (0.62 | ) |     | $            |      (2.75 | ) |
| – Diluted(1)                                                |     | $            |      (0.78 | ) |     | $            |      (0.62 | ) |     | $            |      (2.75 | ) |

____________

(1)

For the years ended December 31, 2024, 2023 and 2022, the total number of share options, warrants and convertible notes excluded from the calculation of diluted earnings per share due to their anti-dilutive nature, are , and , respectively.

20. COMMITMENTS AND CONTINGENCIES Contingent Payment Obligations As of December 31, 2024, the Group does not have any non -cancellablepurchase commitments. The Group has contingency payment obligations under each of the license agreements, such as milestone payments, royalties, research and development funding, if certain condition or milestone is met.

F-32

APTORUM GROUP LIMITED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Stated in U.S. Dollars) 20. COMMITMENTS AND CONTINGENCIES (cont.)

Milestone payments are due upon achievements of specific conditions, such as Investigational New Drugs (“IND”) filing or U.S. Food and Drug Administration (“FDA”) approval, first commercial sale of the licensed products, or other achievements.

| Drug molecules: up to the conditions and milestones of         |     | Amount |            |
|:---------------------------------------------------------------|:----|:-------|-----------:|
| Preclinical to IND filing                                      |     | $      |     30,000 |
| From entering phase 1 to before first commercial sale          |     |        |  2,120,000 |
| First commercial sale                                          |     |        |  1,600,000 |
| Net sales amount more than certain threshold in a year         |     |        | 14,000,000 |
| Subtotal                                                       |     | $      | 17,750,000 |
| Diagnostics technology: up to the conditions and milestones of |     |        |            |
| Before FDA approval                                            |     | $      |